SCHEMBL3011004

SCHEMBL3011004

O=[N+]([O-])c1ccc(S(=O)(=O)C2CCN(c3nc(-c4ccc(F)c(Cl)c4)cs3)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.55
MAPT P10636 4/20 0.55
RAB9A P51151 4/20 0.53
NPC1 O15118 3/20 0.53
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
KMT2A Q03164 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 1/20 0.46
AR P10275 3/20 0.43
KDM1A O60341 2/20 0.42
MAOA P21397 1/20 0.41
EGFR P00533 3/20 0.41
USP2 O75604 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK1 P28482 1/20 0.40
EIF4E P06730 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018138 0.93 RAB9A (0.53) SMN1; SMN2MAPTRAB9ANPC1MEN1
SCHEMBL3009366 0.92 RAB9A (0.55) SMN1; SMN2MAPTRAB9ANPC1MEN1
SCHEMBL3021995 0.92 RAB9A (0.55) SMN1; SMN2MAPTRAB9ANPC1MEN1
SCHEMBL3016438 0.91 SMN1; SMN2 (0.47) SMN1; SMN2MAPTRAB9ANPC1MEN1
SCHEMBL3012909 0.91 SMN1; SMN2 (0.50) SMN1; SMN2MAPTRAB9ANPC1MEN1
SCHEMBL3004591 0.90 SMN1; SMN2 (0.57) SMN1; SMN2MAPTRAB9ANPC1MEN1
SCHEMBL3011801 0.90 SMN1; SMN2 (0.51) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL3016899 0.90 SMN1; SMN2 (0.44) SMN1; SMN2MAPTRAB9ANPC1MEN1
SCHEMBL3020027 0.89 MAPT (0.69) SMN1; SMN2MAPTRAB9ANPC1MEN1
SCHEMBL3007916 0.89 SMN1; SMN2 (0.58) SMN1; SMN2MAPTRAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885MAPT 18/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.